Share chart Oyster Point Pharma, Inc.
Extended chart
Simple chart
About
Oyster Point Pharma, Inc., биофармацевтическая компания на клинической стадии, занимается открытием, разработкой и коммерциализацией фармацевтических методов лечения заболеваний глазной поверхности в Соединенных Штатах. Ведущим кандидатом на продукцию компании является OC-01, агонист никотиновых рецепторов ацетилхолина, который завершил клинические испытания фазы III для лечения признаков и симптомов болезни сухого глаза. Также разрабатывается OC-01 для нейротрофической кератопатии. Компания Oyster Point Pharma, Inc. more details| IPO date | 2019-10-31 |
|---|---|
| ISIN | US69242L1061 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.oysterpointrx.com |
| Цена ао | 11.17 |
| Change price per day: | 0% (11.17) |
|---|---|
| Change price per week: | 0% (11.17) |
| Change price per month: | 0% (11.17) |
| Change price per 3 month: | +58.89% (7.03) |
| Change price per half year: | +147.67% (4.51) |
| Change price per year: | -29.75% (15.9) |
| Change price per 3 year: | -31.39% (16.28) |
| Change price per 5 year: | 0% (11.17) |
| Change price per 10 year: | 0% (11.17) |
| Change price per year to date: | +0.4496% (11.12) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| NEA Management Company, LLC | 5925287 | 22.07 |
| Invus Financial Advisors, LLC | 2768586 | 10.31 |
| RTW Investments LP | 2044312 | 7.62 |
| Point72 Asset Management, L.P. | 1805387 | 6.73 |
| Paradigm Biocapital Advisors LP | 1648316 | 6.14 |
| Kohlberg Kravis Roberts & Co. L.P. | 1039622 | 3.87 |
| Telemark Asset Management, LLC | 777026 | 2.89 |
| GW&K Investment Management, LLC | 564856 | 2.1 |
| COWEN AND COMPANY, LLC | 509794 | 1.9 |
| Blackrock Inc. | 504373 | 1.88 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Daniel Lochner M.B.A. | CFO & Chief Bus. Officer | 642k | 1982 (43 years) |
| Mr. George Donato M.B.A. | Sr. VP of CMC & Operations | N/A | |
| Dr. Eric Carlson Ph.D. | Chief Scientific Officer | N/A | |
| Mr. Barry Rosenfeld J.D. | Sr. VP & Gen. Counsel | N/A | |
| Ms. Raegan A. McClain CCEP, J.D., L.L.M. | Chief Compliance & Privacy Officer | N/A | |
| Dr. Jeffrey Nau MMS, Ph.D. | Pres, CEO & Director | 962.85k | 1975 (50 years) |
| Arty Ahmed | VP of Investor relations | N/A | |
| Ms. Karen Castillo-Paff | VP of Communications & PR | N/A | |
| Mr. Dave Benadon | Chief HR Officer | N/A | |
| Ms. Loni Da Silva M.S. | Sr. VP of Regulatory Affairs | N/A |
Address: United States, Princeton, NJ , 202 Carnegie Center - open in Google maps, open in Yandex maps
Website: https://www.oysterpointrx.com
Website: https://www.oysterpointrx.com
